2020 Tourette Syndrome Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Tourette Syndrome pipeline report presents a comprehensive overview of the research and development of Tourette Syndrome drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, one drug in Phase 1, five drugs in Phase 2 and two drugs in Phase 3
As of February 2020, the Tourette Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Tourette Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha 2A adrenergic receptor agonist; Cannabinoid receptor modulators; Dopamine D1 receptor antagonist; dopamine inhibitor; GABA-A receptor antagonist; gamma-aminobutyric acid (GABA) inhibitor; monoacylglycerol lipase inhibitor; noradrenaline transporters; Vesicular monoamine transporter 2 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Tourette Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Tourette Syndrome pipeline drugs profiled in the report include- (amfetamine + guanfacine), alpha-dihydrotetrabenazine, sepranolone (UC1010), CPP-115, ecopipam (PSYRX 101), ABX-1431, valbenazine (NBI-98854), bevantolol (SOM-3355), deutetrabenazine (SD-809), THX-120, THX-110 (dronabinol + palmitoylethanolamide)
As of February 2020, the Tourette Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Tourette Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha 2A adrenergic receptor agonist; Cannabinoid receptor modulators; Dopamine D1 receptor antagonist; dopamine inhibitor; GABA-A receptor antagonist; gamma-aminobutyric acid (GABA) inhibitor; monoacylglycerol lipase inhibitor; noradrenaline transporters; Vesicular monoamine transporter 2 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Tourette Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Tourette Syndrome development
- Tourette Syndrome pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Tourette Syndrome pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Tourette Syndrome pipeline candidates included
- Business overview and snapshot of all companies involved in Tourette Syndrome pipeline are included
- Latest market and pipeline developments are provided in the report
Tourette Syndrome pipeline drugs profiled in the report include- (amfetamine + guanfacine), alpha-dihydrotetrabenazine, sepranolone (UC1010), CPP-115, ecopipam (PSYRX 101), ABX-1431, valbenazine (NBI-98854), bevantolol (SOM-3355), deutetrabenazine (SD-809), THX-120, THX-110 (dronabinol + palmitoylethanolamide)
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Tourette Syndrome Condition
2.3 Tourette Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Tourette Syndrome pipeline therapeutics
2.5 Phase wise Tourette Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Tourette Syndrome Pipeline Products
2.7 Route of Administration of Tourette Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Abide Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.2 Adeptio Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Asarina Pharma AB Overview, Contacts and ASD Pipeline Drugs
3.4 Catalyst Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Emalex Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.6 KemPharm Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Neurocrine Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.8 SOM Biotech SL Overview, Contacts and ASD Pipeline Drugs
3.9 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Therapix Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 (amfetamine + guanfacine) Drug Details
4.1.1 (amfetamine + guanfacine) Current Status
4.1.2 (amfetamine + guanfacine) Drug Overview
4.1.3 (amfetamine + guanfacine) Mechanism of Action
4.1.4 (amfetamine + guanfacine) Licensing/Collaboration Companies
4.1.5 (amfetamine + guanfacine) Clinical Trials
4.2 alpha-dihydrotetrabenazine Drug Details
4.2.1 alpha-dihydrotetrabenazine Current Status
4.2.2 alpha-dihydrotetrabenazine Drug Overview
4.2.3 alpha-dihydrotetrabenazine Mechanism of Action
4.2.4 alpha-dihydrotetrabenazine Licensing/Collaboration Companies
4.2.5 alpha-dihydrotetrabenazine Clinical Trials
4.3 sepranolone (UC1010) Drug Details
4.3.1 sepranolone (UC1010) Current Status
4.3.2 sepranolone (UC1010) Drug Overview
4.3.3 sepranolone (UC1010) Mechanism of Action
4.3.4 sepranolone (UC1010) Licensing/Collaboration Companies
4.3.5 sepranolone (UC1010) Clinical Trials
4.4 CPP-115 Drug Details
4.4.1 CPP-115 Current Status
4.4.2 CPP-115 Drug Overview
4.4.3 CPP-115 Mechanism of Action
4.4.4 CPP-115 Licensing/Collaboration Companies
4.4.5 CPP-115 Clinical Trials
4.5 ecopipam (PSYRX 101) Drug Details
4.5.1 ecopipam (PSYRX 101) Current Status
4.5.2 ecopipam (PSYRX 101) Drug Overview
4.5.3 ecopipam (PSYRX 101) Mechanism of Action
4.5.4 ecopipam (PSYRX 101) Licensing/Collaboration Companies
4.5.5 ecopipam (PSYRX 101) Clinical Trials
4.6 ABX-1431 Drug Details
4.6.1 ABX-1431 Current Status
4.6.2 ABX-1431 Drug Overview
4.6.3 ABX-1431 Mechanism of Action
4.6.4 ABX-1431 Licensing/Collaboration Companies
4.6.5 ABX-1431 Clinical Trials
4.7 valbenazine (NBI-98854) Drug Details
4.7.1 valbenazine (NBI-98854) Current Status
4.7.2 valbenazine (NBI-98854) Drug Overview
4.7.3 valbenazine (NBI-98854) Mechanism of Action
4.7.4 valbenazine (NBI-98854) Licensing/Collaboration Companies
4.7.5 valbenazine (NBI-98854) Clinical Trials
4.8 bevantolol (SOM-3355) Drug Details
4.8.1 bevantolol (SOM-3355) Current Status
4.8.2 bevantolol (SOM-3355) Drug Overview
4.8.3 bevantolol (SOM-3355) Mechanism of Action
4.8.4 bevantolol (SOM-3355) Licensing/Collaboration Companies
4.8.5 bevantolol (SOM-3355) Clinical Trials
4.9 deutetrabenazine (SD-809) Drug Details
4.9.1 deutetrabenazine (SD-809) Current Status
4.9.2 deutetrabenazine (SD-809) Drug Overview
4.9.3 deutetrabenazine (SD-809) Mechanism of Action
4.9.4 deutetrabenazine (SD-809) Licensing/Collaboration Companies
4.9.5 deutetrabenazine (SD-809) Clinical Trials
4.10 THX-120 Drug Details
4.10.1 THX-120 Current Status
4.10.2 THX-120 Drug Overview
4.10.3 THX-120 Mechanism of Action
4.10.4 THX-120 Licensing/Collaboration Companies
4.10.5 THX-120 Clinical Trials
4.11 THX-110 (dronabinol + palmitoylethanolamide) Drug Details
4.11.1 THX-110 (dronabinol + palmitoylethanolamide) Current Status
4.11.2 THX-110 (dronabinol + palmitoylethanolamide) Drug Overview
4.11.3 THX-110 (dronabinol + palmitoylethanolamide) Mechanism of Action
4.11.4 THX-110 (dronabinol + palmitoylethanolamide) Licensing/Collaboration Companies
4.11.5 THX-110 (dronabinol + palmitoylethanolamide) Clinical Trials
5. LATEST TOURETTE SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Tourette Syndrome Condition
2.3 Tourette Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Tourette Syndrome pipeline therapeutics
2.5 Phase wise Tourette Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Tourette Syndrome Pipeline Products
2.7 Route of Administration of Tourette Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Abide Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.2 Adeptio Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Asarina Pharma AB Overview, Contacts and ASD Pipeline Drugs
3.4 Catalyst Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Emalex Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.6 KemPharm Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Neurocrine Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.8 SOM Biotech SL Overview, Contacts and ASD Pipeline Drugs
3.9 Teva Pharmaceutical Industries Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Therapix Biosciences Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 (amfetamine + guanfacine) Drug Details
4.1.1 (amfetamine + guanfacine) Current Status
4.1.2 (amfetamine + guanfacine) Drug Overview
4.1.3 (amfetamine + guanfacine) Mechanism of Action
4.1.4 (amfetamine + guanfacine) Licensing/Collaboration Companies
4.1.5 (amfetamine + guanfacine) Clinical Trials
4.2 alpha-dihydrotetrabenazine Drug Details
4.2.1 alpha-dihydrotetrabenazine Current Status
4.2.2 alpha-dihydrotetrabenazine Drug Overview
4.2.3 alpha-dihydrotetrabenazine Mechanism of Action
4.2.4 alpha-dihydrotetrabenazine Licensing/Collaboration Companies
4.2.5 alpha-dihydrotetrabenazine Clinical Trials
4.3 sepranolone (UC1010) Drug Details
4.3.1 sepranolone (UC1010) Current Status
4.3.2 sepranolone (UC1010) Drug Overview
4.3.3 sepranolone (UC1010) Mechanism of Action
4.3.4 sepranolone (UC1010) Licensing/Collaboration Companies
4.3.5 sepranolone (UC1010) Clinical Trials
4.4 CPP-115 Drug Details
4.4.1 CPP-115 Current Status
4.4.2 CPP-115 Drug Overview
4.4.3 CPP-115 Mechanism of Action
4.4.4 CPP-115 Licensing/Collaboration Companies
4.4.5 CPP-115 Clinical Trials
4.5 ecopipam (PSYRX 101) Drug Details
4.5.1 ecopipam (PSYRX 101) Current Status
4.5.2 ecopipam (PSYRX 101) Drug Overview
4.5.3 ecopipam (PSYRX 101) Mechanism of Action
4.5.4 ecopipam (PSYRX 101) Licensing/Collaboration Companies
4.5.5 ecopipam (PSYRX 101) Clinical Trials
4.6 ABX-1431 Drug Details
4.6.1 ABX-1431 Current Status
4.6.2 ABX-1431 Drug Overview
4.6.3 ABX-1431 Mechanism of Action
4.6.4 ABX-1431 Licensing/Collaboration Companies
4.6.5 ABX-1431 Clinical Trials
4.7 valbenazine (NBI-98854) Drug Details
4.7.1 valbenazine (NBI-98854) Current Status
4.7.2 valbenazine (NBI-98854) Drug Overview
4.7.3 valbenazine (NBI-98854) Mechanism of Action
4.7.4 valbenazine (NBI-98854) Licensing/Collaboration Companies
4.7.5 valbenazine (NBI-98854) Clinical Trials
4.8 bevantolol (SOM-3355) Drug Details
4.8.1 bevantolol (SOM-3355) Current Status
4.8.2 bevantolol (SOM-3355) Drug Overview
4.8.3 bevantolol (SOM-3355) Mechanism of Action
4.8.4 bevantolol (SOM-3355) Licensing/Collaboration Companies
4.8.5 bevantolol (SOM-3355) Clinical Trials
4.9 deutetrabenazine (SD-809) Drug Details
4.9.1 deutetrabenazine (SD-809) Current Status
4.9.2 deutetrabenazine (SD-809) Drug Overview
4.9.3 deutetrabenazine (SD-809) Mechanism of Action
4.9.4 deutetrabenazine (SD-809) Licensing/Collaboration Companies
4.9.5 deutetrabenazine (SD-809) Clinical Trials
4.10 THX-120 Drug Details
4.10.1 THX-120 Current Status
4.10.2 THX-120 Drug Overview
4.10.3 THX-120 Mechanism of Action
4.10.4 THX-120 Licensing/Collaboration Companies
4.10.5 THX-120 Clinical Trials
4.11 THX-110 (dronabinol + palmitoylethanolamide) Drug Details
4.11.1 THX-110 (dronabinol + palmitoylethanolamide) Current Status
4.11.2 THX-110 (dronabinol + palmitoylethanolamide) Drug Overview
4.11.3 THX-110 (dronabinol + palmitoylethanolamide) Mechanism of Action
4.11.4 THX-110 (dronabinol + palmitoylethanolamide) Licensing/Collaboration Companies
4.11.5 THX-110 (dronabinol + palmitoylethanolamide) Clinical Trials
5. LATEST TOURETTE SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
